المؤلفون: Wang, Qu

مصطلحات موضوعية: Computer Science - Machine Learning

الوصف: Large-scale Dynamic Networks (LDNs) are becoming increasingly important in the Internet age, yet the dynamic nature of these networks captures the evolution of the network structure and how edge weights change over time, posing unique challenges for data analysis and modeling. A Latent Factorization of Tensors (LFT) model facilitates efficient representation learning for a LDN. But the existing LFT models are almost based on Canonical Polyadic Factorization (CPF). Therefore, this work proposes a model based on Tensor Ring (TR) decomposition for efficient representation learning for a LDN. Specifically, we incorporate the principle of single latent factor-dependent, non-negative, and multiplicative update (SLF-NMU) into the TR decomposition model, and analyze the particular bias form of TR decomposition. Experimental studies on two real LDNs demonstrate that the propose method achieves higher accuracy than existing models.

الوصول الحر: http://arxiv.org/abs/2304.08798Test

المؤلفون: Wang Qu, Zimin Liu, Xiaobing Chen, Bo Liu, YunBo Zhao, Hao Yan, Xiujuan Qu, Shengmian Li, Aimin Zang, Yongkun Sun, Liangjun Zhu, Aiping Zhou

المصدر: BMC Cancer, Vol 24, Iss 1, Pp 1-8 (2024)

مصطلحات موضوعية: Colorectal cancer, Regorafenib, Immunotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Abstract Objective To evaluate the efficacy and safety of regorafenib monotherapy or in combination with immune-checkpoint inhibitor while treating Chinese patients with metastatic colorectal cancer (mCRC): a real-world study. Methods The data of patients with metastatic colorectal cancer who received regorafenib-containing regimen as the third or later line treatment at ten Chinese hospitals from Aug 2017 to Jun 2020 were retrospectively analyzed, including dosing details, survival data as well as adverse events. Survival analysis was further performed for patients administrated with regorafenib monotherapy and combined with an immune-checkpoint inhibitor based on Kaplan-Meier and Cox regression methods. The primary endpoint was overall survival. Results A total of 537 patients were included with a median age of 61, among whom 376 received regorafenib monotherapy and 245 received regorafenib combined with immune-checkpoint inhibitors. The clinicopathological characteristics of the two groups at baseline were mainly balanced. No significant difference in progression-free survival (PFS) was observed in patients receiving regorafenib monotherapy or combination therapy (3.8 vs. 5.5 months, p = 0.170). In contrast, patients receiving combination therapy had a more prolonged overall survival (OS) than those receiving regorafenib monotherapy (13.5 vs. 10.0 months, p = 0.001). The treatment regimen and regorafenib dosage were significant prognostic factors in the multivariate analysis. Significant benefits in PFS and OS were achieved in KRAS mutant and anti-angiogenesis treatment-naïve subgroups receiving combination therapy compared to monotherapy. No apparent increase was recorded in treatment-related adverse events in patients receiving combination therapy. Conclusion Regorafenib plus an immune-checkpoint inhibitor has already been a widely adopted strategy in the later-line treatment for mCRC in the real world. The combination therapy yielded a significantly prolonged overall survival than regorafenib alone, with a manageable safety profile in Chinese patients, and warrants further investigation. Trial registration ClinicalTrials.gov Identifier: NCT04835324. Registered 6th April 2021.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1471-2407Test

الوصول الحر: https://doaj.org/article/7bbb87cb91cb48f4b2519a41ace9f1aeTest

المؤلفون: Ruiyang Xie, Bingqing Shang, Hongzhe Shi, Xingang Bi, Yan Song, Wang Qu, Hongsong Bai, Linjun Hu, Jie Wu, Honglei Cui, Gan Du, Lei Guo, Shan Zheng, Jianming Ying, Changling Li, Jianhui Ma, Aiping Zhou, Jianzhong Shou

المصدر: Cancer Medicine, Vol 12, Iss 24, Pp 21807-21819 (2023)

مصطلحات موضوعية: efficacy prediction, metastatic clear cell renal cell carcinoma, neutrophil extracellular traps, systemic therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Abstract Background The efficacy of systemic therapy regimens, such as immune checkpoint inhibitors and tyrosine kinase inhibitors (IO‐TKI) and targeted therapy, for metastatic clear cell renal cell carcinoma (ccRCC) remains unpredictable due to the lack of effective biomarkers. Neutrophil extracellular trap (NET) plays an important role in promoting ccRCC. This study explores the NET predictive value of the efficacy in metastatic ccRCC. Methods In this retrospective study, patients with metastatic ccRCC who received targeted drugs and IO‐TKI were included. Immunofluorescence staining was utilized to quantify the levels of tissue NETs through cell counts of H3Cit(+) and MPO(+) cells. Results A total of 183 patients with metastatic ccRCC were enrolled, including 150 patients who received TKIs and 33 patients who received IO‐TKI. The levels of NETs in tumor tissue were significantly higher than in para‐tumor tissue (p

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2045-7634Test

الوصول الحر: https://doaj.org/article/c363eff574ea4eaa8124c12a23691c7eTest

المؤلفون: Gan Du, Zhichao Jiang, Wang Qu, Jin Zhang, Shan Zheng, Yueping Liu, Aiping Zhou, Hongzhe Shi, Jianzhong Shou

المصدر: Heliyon, Vol 10, Iss 6, Pp e27685- (2024)

مصطلحات موضوعية: Muscle-invasive bladder cancer, Neoadjuvant therapy, Antibody-drug conjugate, Bladder preservation, Case report, Science (General), Q1-390, Social sciences (General), H1-99

الوصف: Background: The study of bladder preservation for muscle-invasive bladder cancer (MIBC) mainly focuses on the T2 stage, which remains difficult in the T3 and T4 stage. Pembrolizumab has been applied as neoadjuvant therapy followed by radical cystectomy for MIBC, gaining encouraging results in the phase II study. Disitamab vedotin, an antibody-drug conjugate (ADC), also achieved promising efficacy for refractory bladder cancer. However, the neoadjuvant therapy strategy of these drugs for bladder sparing remains further exploration. Case presentation: A patient with locally advanced MIBC at our institute underwent a neoadjuvant therapeutic regimen followed by transurethral resection of bladder tumor (TURBT) and concurrent chemoradiotherapy. In light of limited initial efficacy, we enacted an adaptive shift in the neoadjuvant treatment strategy, transitioning from a combination of gemcitabine, cis-platinum, and pembrolizumab to disitamab vedotin with pembrolizumab. This approach ultimately achieved bladder preservation, complete response, and a remarkable 1-year disease-free survival (DFS). Conclusion: Proactive evaluation in the early stages of tumor downstaging can serve as a guiding principle for neoadjuvant strategies. This is the first successful case of neoadjuvant pembrolizumab combined with disitamab vedotin and chemotherapy in MIBC patients achieving complete response and bladder preservation.

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S2405844024037162Test; https://doaj.org/toc/2405-8440Test

الوصول الحر: https://doaj.org/article/33d79814b50a4813bdd2198c2e9734a6Test

المؤلفون: Zhang, Cong-Cong, Zhang, Jia-Yi, Feng, Jing-Ru, Liu, Si-Ting, Ding, Si-Jing, Ma, Liang, Wang, Qu-Quan

المساهمون: National Natural Science Foundation of China, Ministry of Science and Technology of the People's Republic of China

المصدر: Nanoscale ; volume 16, issue 12, page 5960-5975 ; ISSN 2040-3364 2040-3372

الوصف: In this review, the basic principles of plasmon-enhanced SHG, different methods to enhance the SHG intensity of metal nanostructures, and related applications of SHG based on metal nanostructures are introduced.

الإتاحة: https://doi.org/10.1039/d3nr06675dTest
http://pubs.rsc.org/en/content/articlepdf/2024/NR/D3NR06675DTest

المؤلفون: Wang, Qu, Fu, Meixia, Wang, Jianquan, Sun, Lei, Huang, Rong, Li, Xianda, Jiang, Zhuqing, Huang, Yan, Jiang, Changhui

المصدر: Defence Technology ; volume 33, page 573-587 ; ISSN 2214-9147

مصطلحات موضوعية: Metals and Alloys, Mechanical Engineering, Ceramics and Composites, Computational Mechanics

الإتاحة: https://doi.org/10.1016/j.dt.2023.03.001Test
https://api.elsevier.com/content/article/PII:S2214914723000533?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2214914723000533?httpAccept=text/plainTest

المؤلفون: Wen Zhang, Haitao Zhou, Jun Jiang, Yuelu Zhu, Shuangmei Zou, Liming Jiang, Yuan Tang, Jianwei Liang, Yongkun Sun, Zhichao Jiang, Wang Qu, Ying Li, Aiping Zhou

المصدر: BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)

مصطلحات موضوعية: Neoadjuvant chemotherapy, Locally advanced rectal cancer, Pathological complete response, FOLFOXIRI, Down-staging, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Abstract Purpose Chemoradiotherapy (CRT) remains the standard treatment for locally advanced rectal cancer (LARC). This phase 2 clinical trial was designed to evaluate the efficacy and safety of neoadjuvant triplet chemotherapy with mFOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan) in LARC. Patients and methods The patients with LARC (the lower edge more than 5 cm from the anal verge) received up to 5 cycles of mFOLFOXIRI. MRI was performed to assess the baseline and postchemotherapy TN stage. Radical resection was performed within 4–6 weeks from the last dose of chemotherapy if the tumor shrank or remained stable. Adjuvant chemotherapy with mFOLFOX6 or XELOX was recommended. Postoperative radiation was planned for R1 resection, ypT4b, ypN2 and a positive CRM. The primary endpoint was the pathological complete response (pCR) rate. Results From February 2016 to March 2019, 50 patients were enrolled. Forty-eight (96%) were clinically node-positive, 28 (56.5%) with MRF invasion and 39 (78.4%) were EMVI positive. The median cycle of neoadjuvant mFOLFOXIRI chemotherapy was 5 (range,1–5). A total of 46/50 (92%) patients underwent total mesorectal excision (TME) surgery, all with R0 resection. The pCR rate was 4.3% (2/46). Twenty-three of 46 (50%) patients with cN + achieved a pathological node-negative status. The proportions of pathologically positive CRM and EMVI were 2.2% and 34.7%, respectively. Adjuvant radiotherapy was given to 14/46 (30.4%) patients. The most common Grade 3 or > toxicities included neutrocytopenia (50%), leukopenia (14%) and diarrhea (12%) during the neoadjuvant chemotherapy period. Clinically meaningful postoperative complications included pneumonia (n = 1), pelvic infection (n = 1) and anastomotic fistula (n = 1). With a median follow-up time of 51.2 months, local recurrences and distant metastases were confirmed in 3 (6.5%) and 9 (19.6%) of cases, respectively. The 3-year disease free survival (DFS) and overall survival (OS)rates were 75.8% and 86.8%. Conclusion Neoadjuvant chemotherapy with mFOLFOXIRI yielded a significant down-staging effect and seemed to be effective in eliminating EMVI and transforming the positive MRF to negative in LARC. The survival results are promising. The long-term follow-up showed promising DFS and OS rates accompanied by a favorable safety profile. Trial registration ClinicalTrials.gov identifier: NCT03443661, 23/02/2018.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1471-2407Test

الوصول الحر: https://doaj.org/article/75ea248036bf4ce0aa752d7f0bcc0e73Test

المؤلفون: Yong Li, Aiping Zhou, Shuoyan Liu, Ming He, Keneng Chen, Ziqiang Tian, Yin Li, Jianjun Qin, Zhen Wang, Haiquan Chen, Hui Tian, Yue Yu, Wang Qu, Liyan Xue, Shun He, Shuhang Wang, Fenglong Bie, Guangyu Bai, Bolun Zhou, Zhaoyang Yang, Huiyao Huang, Yan Fang, Benjamin Li, Xiangrong Dai, Shugeng Gao, Jie He

المصدر: BMC Medicine, Vol 21, Iss 1, Pp 1-12 (2023)

مصطلحات موضوعية: PD-L1, Chemotherapy, Neoadjuvant treatment, Esophageal squamous cell carcinoma (ESCC), Major pathological response (MPR), Medicine

الوصف: Abstract Background A Phase II study was undertaken to evaluate the safety and efficacy of the neoadjuvant socazolimab, a novel PD-L1 inhibitor, in combination with nab-paclitaxel and cisplatin for locally advanced esophageal squamous cell carcinoma (ESCC). Methods Sixty-four patients were randomly divided between the Socazolimab + nab-paclitaxel + cisplatin (TP) arm (n = 32) and the control arm (n = 32), receiving either socazolimab (5 mg/kg intravenously (IV), day 1) or a placebo with nab-paclitaxel (125 mg/m2 IV, day 1/8) and cisplatin (75 mg/m2 IV, day 1) repeated every 21 days for four cycles before surgery. The primary endpoint was major pathological response (MPR), and the secondary endpoints were pathological complete response (pCR), R0 resection rate, event-free survival (EFS), overall survival (OS), and safety. Results A total of 29 (90.6%) patients in each arm underwent surgery, and 29 (100%) and 28 (98.6%) patients underwent R0 resection in the Socazolimab + TP and Placebo + TP arms, respectively. The MPR rates were 69.0 and 62.1% (95% Confidence Interval (CI): 49.1–84.0% vs. 42.4–78.7%, P = 0.509), and the pCR rates were 41.4 and 27.6% (95% CI: 24.1–60.9% vs. 13.5–47.5%, P = 0.311) in the Socazolimab + TP and Placebo + TP arms, respectively. Significantly higher incidence rates of ypT0 (37.9% vs. 3.5%; P = 0.001) and T downstaging were observed in the Socazolimab + TP arm than in the Placebo + TP arm. The EFS and OS outcomes were not mature. Conclusions The neoadjuvant socazolimab combined with chemotherapy demonstrated promising MPR and pCR rates and significant T downstaging in locally advanced ESCC without increasing surgical complication rates. Trial registration Registration name (on clinicaltrials.gov): A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma. Registration number: NCT04460066.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1741-7015Test

الوصول الحر: https://doaj.org/article/95afef0fd3704bb2bf3b853070fbe091Test

المؤلفون: Jie Wu, Rui‐Yang Xie, Li‐Hui Wei, Chuan‐Zhen Cao, Bing‐Qing Shang, You‐Yan Guan, Hong‐Zhe Shi, Wang Qu, Yun Li, Jing Liang, Shan Zheng, Ai‐Ping Zhou, Xiao‐Feng Zhou, Jian‐Zhong Shou, Xin‐Gang Bi

المصدر: Cancer Medicine, Vol 12, Iss 4, Pp 4981-4992 (2023)

مصطلحات موضوعية: multiplex immunofluorescence staining, muscle‐invasive bladder cancer, neoadjuvant chemotherapy, prognosis, tumor‐associated macrophages, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Abstract Background The current study aimed to investigate the dynamic alteration and prognostic significance of tumor‐infiltrating lymphocytes (TILs), tumor‐associated macrophages (TAMs), and PD‐L1 status of immune cells in muscle‐invasive bladder cancer (MIBC) treated with neoadjuvant chemotherapy (NAC). Methods Multiplex immunofluorescence staining was performed to examine CD68+ TAM, CD4+ T cell, CD8+ T cell, FOXP3+ Treg cell, and PD‐L1 expression in paired MIBC tissues (n = 54) before and after NAC. Patients were then divided into definite responders (DR), (≤pT1) and incomplete responders (IR). Results There was no significant difference between DR and IR cohorts for the immune cell infiltration levels at the baseline status. Tobacco history was identified to be associated with worse NAC efficacy. CD68+ (stroma area: p = 0.025; tumor area: p = 0.028; total area: p = 0.013) and CD68+PD‐L1− (stroma area: p = 0.035; tumor area: p = 0.013 total area: p = 0.014) TAMs infiltration levels decreased significantly after NAC, while there was no significant difference of CD68+PD‐L1+ and TILs. The infiltration of CD68+ (p = 0.033), CD68+PD‐L1− (p = 0.033), and CD68+PD‐L1+ (p

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2045-7634Test

الوصول الحر: https://doaj.org/article/4aac1c2dc14b4341b4eb74acf2579825Test

المؤلفون: Guanqin Ma, Deng-Feng Zhang, Qing-Cui Zou, Xiaochun Xie, Ling Xu, Xiao-Li Feng, Xiaohong Li, Jian-Bao Han, Dandan Yu, Zhong-Hua Deng, Wang Qu, Junyi Long, Ming-Hua Li, Yong-Gang Yao, Jianxiong Zeng

المصدر: Cell Discovery, Vol 8, Iss 1, Pp 1-5 (2022)

مصطلحات موضوعية: Cytology, QH573-671

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2056-5968Test

الوصول الحر: https://doaj.org/article/ab6f9b3eb1db4d639db7b5285b6fb977Test